Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 9/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239985 | 0.84 | PIK3CD (0.58) | L3MBTL1PIK3CDACHETSHRRECQL | |
| SCHEMBL20008988 | 0.84 | PIK3CD (0.55) | SMOHTTL3MBTL1PIK3CDGAA | |
| SCHEMBL20009029 | 0.84 | PIK3CD (0.55) | SMOHTTL3MBTL1PIK3CDGAA | |
| SCHEMBL20009023 | 0.84 | PIK3CD (0.55) | SMOHTTL3MBTL1PIK3CDGAA | |
| SCHEMBL252505 | 0.81 | ACHE (0.55) | SMOHTTL3MBTL1PIK3CDACHE | |
| SCHEMBL18080914 | 0.80 | SMO (0.53) | SMOHTTL3MBTL1ACHEGAA | |
| SCHEMBL26814614 | 0.80 | HTT (0.56) | SMOHTTL3MBTL1PIK3CDACHE | |
| SCHEMBL10938522 | 0.79 | ACHE (0.53) | SMOHTTL3MBTL1PIK3CDACHE | |
| SCHEMBL3712727 | 0.79 | HTT (0.62) | SMOHTTL3MBTL1ACHEGAA | |
| SCHEMBL26243687 | 0.78 | PRKCB (0.42) | SMOHTTL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | SMO 1332/4885HTT 832/4885L3MBTL1 555/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | SMO 1332/4885HTT 832/4885L3MBTL1 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.